CLAIMS

1. Use of at least one phosphinic pseudopeptide derivative comprising the amino acid sequence of formula (I) below:



(I)

in which:

- R_2 and R_3, which are identical or different, represent the side chain of a natural or unnatural amino acid, the sequence:



also possibly forming the Pro (proline) residue, and

- R_5 represents a hydrogen atom, a pharmacologically acceptable counterion, or a group capable of forming an *in vivo* hydrolysable phosphinic ester;

for the manufacture of a medicinal product capable of selectively inhibiting the C-terminal site of angiotensin I converting enzyme.

2. Use of a phosphinic pseudopeptide derivative corresponding to formula (II) below:



(II)

in which:

- R_1 represents a protecting group for an amine function, or an amino acid or a peptide protected with a protecting group for an amine function,

- R_2 and R_3, which may be identical or different, represent the side chain of a natural or unnatural amino acid, the sequence:



also possibly forming the Pro residue,

- R_4 represents a hydrogen atom or a pharmacologically acceptable counterion, and

- R_5 represents a hydrogen atom, a pharmacologically acceptable counterion, or a group capable of forming an *in vivo* hydrolysable phosphinic ester;

for the manufacture of a medicinal product capable of selectively inhibiting the C-terminal site of angiotensin I converting enzyme.

3. Use according to Claim 2, in which R_1 represents a protecting group for an amine function chosen from acetyl and benzyloxycarbonyl groups.

4. Use according to any one of Claims 1 to 3, in which R_2 represents the benzyl, methyl or phenylethyl group.

5. Use according to any one of Claims 1 to 4, in which R_3 represents the side chain of alanine, arginine or tryptophan.

6. Use according to any one of Claims 1 to 4, in which the sequence $-NH-CH(R_3)-CO-$ forms the Pro residue:



7. Use according to any one of Claims 1 to 6, in which R_4 and/or R_5 represent(s) a hydrogen atom.

8. Use according to Claim 2, in which the phosphinic pseudopeptide derivative corresponds to the formula:



(pseudo-peptide G)

9. Phosphinic pseudopeptide derivative comprising the amino acid sequence of formula (I) below:



(I)

in which:

- R_2 represents the side chain of a natural or unnatural amino acid,

- the sequence:



forms the Pro residue:



- R_4 represents a hydrogen atom or a pharmacologically acceptable counterion, and

- R_5 represents a hydrogen atom, a pharmacologically acceptable counterion, or a group capable of forming an *in vivo* hydrolysable phosphinic ester.

10. Phosphinic pseudopeptide derivative corresponding to formula (II) below:



(II)

in which:

- R_1 represents a protecting group for an amine function, or an amino acid or a peptide protected with a protecting group for an amine function,

- R_2 represents the side chain of a natural or unnatural amino acid,

- the sequence:



forms the Pro residue:



- R_5 represents a hydrogen atom, a pharmacologically acceptable counterion, or a group capable of forming an *in vivo* hydrolysable phosphinic ester.

11. Phosphinic pseudopeptide derivative of formula:



(pseudo-peptide G)

12. Pharmaceutical composition comprising at least one phosphinic pseudopeptide derivative according to any one of Claims 9 to 11.

13. Pharmaceutical composition, in which the phosphinic pseudopeptide derivative corresponds to the formula:



(pseudo-peptide G)

14. Process for preparing a pseudopeptide of formula:



(II)

in which:

- R_1 represents a protecting group for an amine function, or an amino acid or a peptide protected with a protecting group for an amine function,

- R_2 and R_3, which may be identical or different, represent the side chain of a natural or unnatural amino acid, the sequence:



also possibly forming the Pro residue, and

- R_4 and R_5 represent a hydrogen atom;

which comprises the following steps:

1) reacting a compound of formula (III):



(III)

in which R_1 and R_2 are as defined above, with the compound of formula (IV):



(IV)

in which Ac represents the acetyl group and Et represents the ethyl group, to obtain the compound of formula (V):



(V)

2) converting compound (V) into compound (VI) by reacting compound (V) with sodium borohydride:



(VI)

3) protecting the hydroxyl group of compound (VI) with a protecting group R_5, for example the adamantyl group Ad, to give the compound of formula (VII):



(VII)

4) saponifying compound (VII) to give the compound of formula (VIII):



(VIII)

5) coupling the compound of formula (VIII) with the amino acid of formula (IX) or (X):



(IX)

or



(X)

in which R_3 is as defined above, and

6) removing the protecting group Ad.

15. Process according to Claim 14, in which the peptide coupling step 5) is performed via solid-phase peptide synthesis using as solid phase a resin substituted with the amino acid of formula (IX) or (X).

16. Process for preparing a pseudopeptide of formula:



(II)

in which:

- R_1 represents a protecting group for an amine function, or an amino acid or a peptide protected with a protecting group for an amine function,

- R_2 and R_3, which may be identical or different, represent the side chain of a natural or unnatural amino acid, the sequence:



also possibly forming the Pro residue,

- R_4 represents a hydrogen atom, and

- R_5 represents a group capable of forming an *in vivo* hydrolysable phosphinic ester;

in which the phosphinic function of the pseudopeptide obtained via the process of Claim 14 or 15 is esterified by coupling with an alcohol of formula R_5OH or by reaction with a halide of formula R_5X in which X represents a halogen atom.

17. Compound of formula (VIII):



(VIII)

in which:

- R_1 represents a protecting group for an amine function or an amino acid or a peptide protected with an amine function, and

- R_2 represents the side chain of a natural or unnatural amino acid.